Protocol and statistical analysis plan for the PREOXI trial of preoxygenation with noninvasive ventilation vs oxygen mask.

Short Title: Protocol and Analysis Plan for the PREOXI Trial

Kevin W. Gibbs MD*1, Adit A. Ginde MD MPH*2, Matthew E. Prekker MD MPH3,17, Kevin P. Seitz MD MSc4, Susan B. Stempek PA MBA5, Caleb Taylor MD MPH6, Sheetal Gandotra MD7, Heath White DO MS8, Daniel Resnick-Ault MD2, Akram Khan MD9, Amira Mohmed MD10, Jason C. Brainard MD11, Daniel G. Fein MD12, Neil R. Aggarwal MD13, Micah R. Whitson MD7,26, Stephen J. Halliday MD MSc14, John P. Gaillard MD15,16, Veronika Blinder DO10, Brian E. Driver MD17, Jessica A. Palakshappa MD MS1, Bradley D. Lloyd RRT RRT-ACCS18, Joanne M. Wozniak PA MS5, Matthew C. Exline MD MPH6, Derek W. Russell MD7,25, Shekhar Ghamande MD8, Cori Withers BS2, Kinsley A. Hubel MD9, Ari Moskowitz MD MPH10, Jill Bastman BSN2, Luke Andrea MD10, Peter D. Sottile MD13, David B. Page MD MSPH7, Micah T. Long MD19, Jordan Kugler Goranson MD16, Rishi Malhotra MD10, Brit J. Long MD20, Steven G. Schauer DO MS21, Andrew Connor DO9, Erin Anderson RN2, Kristin Maestas2, Jillian P. Rhoads PhD4, Kelsey Womack PhD4, Brant Imhoff MS22, David R. Janz MD MSc23, Stacy A. Trent, MD MSPH2,24 Wesley H. Self MD MPH18, Todd W. Rice MD MSc4, Matthew W. Semler MD MSc**,4, Jonathan D. Casey MD MSc***4 for the PREOXI investigators and the Pragmatic Critical Care Research Group

*Authors contributed equally

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
** Authors contributed equally

*** A full list of PREOXI investigators is provided in the Supplemental file

1. Section on Pulmonary, Critical Care, Allergy, and immunology, Wake Forest School of Medicine, Winston-Salem, NC, USA

2. Department of Emergency Medicine, University of Colorado School of Medicine Aurora, CO, USA

3. Division of Pulmonary and Critical Care Medicine, Hennepin County Medical Center, Minneapolis, MN, USA

4. Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN, USA

5. Department of Medicine, Division of Pulmonary & Critical Care Medicine, Lahey Hospital & Medical Center, Burlington, MA, USA

6. Pulmonary, Critical Care and Sleep Medicine, The Ohio State University, Columbus, OH, USA

7. Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine University of Alabama at Birmingham, Birmingham, AL, USA

8. Department of Medicine, Division of pulmonary & Critical Care Medicine, Baylor Scott & White Medical Center, Temple, TX, USA

9. Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, Oregon Health & Science University, Portland, OR, USA
10. Division of Critical Care Medicine  Montefiore Medical Center  Bronx, NY, USA

11. Department of Anesthesiology  University of Colorado School of Medicine  Aurora, CO, USA

12. Division of Pulmonary Medicine  Montefiore Medical Center  Bronx, NY, USA

13. Department of Medicine, Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado School of Medicine, Aurora, CO, USA

14. Department of Medicine, Division of Allergy, Pulmonary, and Critical Care Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wi, USA

15. Department of Anesthesiology, Section on Critical Care, Wake Forest School of Medicine, Winston-Salem, NC, USA

16. Department of Emergency Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA

17. Department of Emergency Medicine, Hennepin County Medical Center, Minneapolis, MN, USA

18. Vanderbilt Institute for Clinical and Translational Research, and Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, TN, USA

19. Department of Anesthesiology, University of Wisconsin School of Medicine & Public Health, Madison, WI, USA

20. 59th Medical Wing, United States Air Force, Fort Sam Houston, San Antonio, TX, USA
21. United States Army Institute of Surgical Research, Joint Base San Antonio-Fort Sam Houston, San Antonio, TX, USA

22. Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA

23. University Medical Center New Orleans and the Department of Medicine, Section of Pulmonary/Critical Care Medicine and Allergy/Immunology, Louisiana State University School of Medicine, New Orleans, LA, USA

24. Department of Emergency Medicine, Denver Health Medical Center, Denver, CO, USA

25. Pulmonary Section, Birmingham VA medical Center, Birmingham, AL, USA

26. Department of Emergency Medicine, University of Alabama at Birmingham, Birmingham, AL, USA

**Corresponding Author:**

Kevin W. Gibbs, MD

**Email:**

kgibbs@wakehealth.edu
Address:
2nd Floor Watlington Hall
1 Medical Center Blvd
Winston-Salem, NC. 27157

Author contributions: Study concept and design: KWG, AAG, MWS, JDC; Acquisition of data: all authors; Drafting of the manuscript KWG, AAG, MWS, JDC; Critical revision of the manuscript for important intellectual content: all authors; Study supervision: KWG, AAG, MWS, JDC.

Sources of Funding: The research was funded primarily by the Department of Defense, Defense Health Agency, J9 Office, RESTORAL program. Kevin P. Seitz was supported in part by the NIH (T32HL087738). Jessica A. Palakshappa was supported in part by the NIA (K23AG073529) Matthew W. Semler was supported in part by the NHLBI (K23HL143053). Jonathan D. Casey was supported in part by the NHLBI (K23HL153584). Derek Russell was supported in part by the NHLBI (K08HL148514-01A1). Data collection utilized the Research Electronic Data Capture (REDCap) tool developed and maintained with Vanderbilt Institute for Clinical and Translational Research grant support (UL1 TR000445 from NCATS/NIH). The funding institutions had no role in (1) conception, design, or conduct of the study, (2) collection, management, analysis, interpretation, or presentation of the data. The views expressed are those of the author and do not reflect the official views or policy of the Department of Defense, its Components. The authors do not have any financial interest in the companies whose
materials are discussed in this publication, and no federal endorsement of the
companies and materials is intended.

Conflicts of Interest and Financial Disclosures: Kevin W. Gibbs MD reports financial
support and travel were provided by US Department of Defense. Adit. A. Ginde MD
MPH reports financial support was provided by US Department of Defense. Matthew E.
Prekker MD MPH reports financial support was provided by US Department of Defense.
Kevin P. Seitz MD MSc reports financial support was provided by National Heart Lung
and Blood Institute. Susan B. Stempek PA MBA reports financial support was provided
by American College of Chest Physicians. Akram Khan MD reports financial support
was provided by United Therapeutics Corporation. Akram Khan MD reports financial
support was provided by 4D Medicine Ltd. Akram Khan MD reports financial support
was provided by Regeneron Pharmaceuticals Inc. Akram Khan MD reports financial
support was provided by Roche. Akram Khan MD reports financial support was
provided by Dompé pharmaceutical. Jessica A. Palakshappa MD MS reports financial
support was provided by National Institute on Aging. Joanne M. Wozniak PA MS reports
was provided by American College of Chest Physicians. Matthew C. Exline MD, MPH
reports financial support was provided by Abbott Laboratories. Derek W. Russell MD
reports financial support was provided by National Heart Lung and Blood Institute.
Shekar Ghamande MD reports financial support was provided by US Department of
Defense. Ari Moskowitz MD MPH reports financial support was provided by National
Heart Lung and Blood Institute. Jill Bastman BSN reports financial support was provided
by US Department of Defense. Micah T. Long MD reports financial support was provided by pocket cards. Steven G. Schauer DO MS reports was provided by US Department of Defense. David Janz MD MSc reports financial support was provided by US Department of Defense. Matthew W. Semler MD MSc reports financial support was provided by US Department of Defense. Matthew W. Semler MD MSc reports financial support was provided by National Heart Lung and Blood Institute. Jonathan D. Casey MD MSc reports was provided by US Department of Defense. Jonathan D. Casey MD MSc reports travel was provided by Fisher & Paykel Healthcare Inc. Todd W Rice MD MSc reports a relationship with Cumberland Pharmaceuticals Inc that includes: consulting or advisory and equity or stocks. Derek W. Russell MD reports a relationship with Achieve Life Science Inc that includes: equity or stocks. Matthew W. Semler MD MSc reports a relationship with Baxter International Inc that includes: consulting or advisory.

Keywords for indexing: Endotracheal intubation, non-invasive positive pressure ventilation, critical illness, respiratory failure, oxygen

Subject Descriptor Number: 4.4 Clinical Trials in Critical Care Medicine

Manuscript Word Count (body only): 4060

Abstract Word Count: 243

Supplemental digital content is available for this article.
HIGHLIGHTS

- Hypoxemia is common during emergency tracheal intubation
- Supplemental oxygen prior to intubation (preoxygenation) reduces risk of hypoxemia
- The PREOXI trial compares noninvasive ventilation vs oxygen mask preoxygenation
- This protocol describes the design, methods, and planned analyses
- PREOXI is the largest trial of preoxygenation for emergency intubation to date
ABSTRACT

Background: Hypoxemia is a common and life-threatening complication during emergency tracheal intubation of critically ill adults. The administration of supplemental oxygen prior to the procedure (“preoxygenation”) decreases the risk of hypoxemia during intubation.

Research Question: Whether preoxygenation with noninvasive ventilation prevents hypoxemia during tracheal intubation of critically ill adults, compared to preoxygenation with oxygen mask, remains uncertain.

Study Design and Methods: The PRagmatic trial Examining OXygenation prior to Intubation (PREOXI) is a prospective, multicenter, non-blinded randomized comparative effectiveness trial being conducted in 7 emergency departments and 17 intensive care units across the United States. The trial compares preoxygenation with noninvasive ventilation versus oxygen mask among 1300 critically ill adults undergoing emergency tracheal intubation. Eligible patients are randomized in a 1:1 ratio to receive either noninvasive ventilation or an oxygen mask prior to induction. The primary outcome is the incidence of hypoxemia, defined as a peripheral oxygen saturation <85% between induction and 2 minutes after intubation. The secondary outcome is the lowest oxygen saturation between induction and 2 minutes after intubation. Enrollment began on 10 March 2022 and is expected to conclude in 2023.

Interpretation: The PREOXI trial will provide important data on the effectiveness of noninvasive ventilation and oxygen mask preoxygenation for the prevention of hypoxemia during emergency tracheal intubation. Specifying the protocol and statistical
analysis plan prior to the conclusion of enrollment increases the rigor, reproducibility, and interpretability of the trial.

Clinical trial registration number: NCT05267652
INTRODUCTION

Life-threatening hypoxemia occurs in 10-20% of emergency tracheal intubations in the Emergency Department (ED) and Intensive Care Unit (ICU). Hypoxemia during intubation is associated with an increased risk of cardiac arrest and death. Identifying interventions to prevent hypoxemia during emergency tracheal intubation is a high priority for clinicians and researchers. Because patients are typically apneic between induction of anesthesia and intubation but continue to consume oxygen, the oxygen content in the lungs at the time of induction is a primary determinant of whether the patient will experience hypoxemia. Preoxygenation, the administration of supplemental oxygen prior to induction of anesthesia, increases the oxygen content in the lung at induction and decreases the risk of hypoxemia. In current clinical practice, preoxygenation for emergency tracheal intubation of critically ill adults is most commonly administered using either an oxygen mask or noninvasive ventilation.

Preoxygenation with an oxygen mask is typically performed using either a non-rebreather mask or a bag-mask device. A non-rebreather mask is a loose-fitting mask with an oxygen reservoir connected to an oxygen source. A bag-mask device is a mask capable of forming a tight seal over the mouth when held in place by a clinician and can be used to provide supplemental oxygenation alone, or both supplemental oxygen and manual ventilation. Both types of oxygen mask can deliver up to 100% oxygen, are simple to set up, and have low potential for gastric insufflation. However, oxygen masks may deliver oxygen less effectively in critically ill patients when tachypnea, high minute ventilation, and poor mask seal allow the entrainment of ambient air with resulting alveolar oxygen concentrations as low as 50%.
Preoxygenation is also routinely administered via noninvasive ventilation, in which a tight-fitting mask is connected to a machine capable of providing both 100% oxygen and positive pressure ventilation. Compared to an oxygen mask, noninvasive ventilation may reduce air entrainment by delivering a higher inspiratory flow rate of oxygen and by minimizing leaks. Additionally, noninvasive ventilation increases the mean airway pressure and recruits atelectatic lung, potentially reducing shunting. Compared with an oxygen mask, noninvasive ventilation may take longer to initiate and may potentially increase the risk of gastric insufflation and aspiration.

Two small, randomized trials have compared these two approaches to preoxygenation. The first trial found that, among 53 ICU patients undergoing tracheal intubation in two hospitals in France, noninvasive ventilation increased the lowest oxygen saturation compared to an oxygen mask (mean lowest oxygen saturation 93% vs. 81%, respectively, P<0.001) with no difference between groups in the incidence of aspiration (6% vs. 8%).\(^{11}\) Among 201 ICU patients in 6 hospitals in France, the second trial found no difference in the severity of illness in the 7 days after intubation and an incidence of hypoxemia during intubation of 18.4% in the noninvasive ventilation group versus 27.7% in the oxygen mask group (P = 0.10).\(^{12}\) Thus, whether noninvasive ventilation for preoxygenation in critically ill adults undergoing emergency tracheal intubation decreases the incidence of hypoxemia compared to an oxygen mask remains unknown. Therefore, we designed the PRagmatic trial Examining OXygenation prior to Intubation (PREOXI) to test the hypothesis that, among critically ill adults undergoing emergency tracheal intubation in the ED and ICU, preoxygenation with noninvasive
ventilation will decrease the incidence of hypoxemia compared to preoxygenation with an oxygen mask.

METHODS AND ANALYSIS

This manuscript was written in accordance with Standard Protocol Items: Recommendations for Intervventional Trials (SPIRIT) guidelines (see Table 1 and online supplement file 1, section 1). 13

Funding:

Funding for this trial was provided by the Department of Defense, Defense Health Agency, J9 Office, RESTORAL program. The funder has no role in study design or conduct, data collection or analysis.

Patient and public involvement:

Materials used to communicate about the study with patients and families were developed with input from the Vanderbilt Community Engaged Research Core, which includes input from patients and community members. Study authors will disseminate the results of this study online and via social media in forms suitable for public understanding.

Study Design:
PREOXI is a pragmatic, multicenter, non-blinded, parallel-group, randomized trial comparing preoxygenation with noninvasive ventilation to preoxygenation with an oxygen mask among critically ill adults undergoing emergency tracheal intubation in the ED and ICU. The primary outcome is the incidence of hypoxemia, defined as a peripheral oxygen saturation < 85% between induction of anesthesia and two minutes after intubation. The trial is conducted by the Pragmatic Critical Care Research Group (www.pragmaticcriticalcare.org). An independent data and safety monitoring board (DSMB) is monitoring the progress and safety of the trial. The trial was registered prior to initiation of enrollment (ClinicalTrials.gov identifier: NCT05267652).

**Study Population:**

Patients located in a participating ED or ICU who are undergoing tracheal intubation using a laryngoscope and sedation are eligible. Patients are excluded if they are known to be less than 18 years old, are known to be pregnant or a prisoner, require positive pressure ventilation for apnea or hypopnea, or have an immediate need for tracheal intubation that precludes performance of study procedures, or if the clinician performing the procedure (referred to as the “operator”) determines that preoxygenation with noninvasive ventilator or an oxygen mask is either required or contraindicated.

Complete lists of inclusion and exclusion criteria are provided in Table 2.

**Randomization and treatment allocation:**

Patients are randomized in a 1:1 ratio to undergo preoxygenation with noninvasive ventilator vs oxygen mask in permuted blocks of variable size, stratified by
study site. Study-group assignments are generated using a computerized randomization sequence, placed in sequentially numbered opaque envelopes, and distributed to enrolling sites. Before opening the envelope, the operator determines that the patient meets eligibility criteria. Study group assignment remains concealed to study personnel and treating clinicians until after the decision has been made to enroll the patient and the envelope is opened. Patients are considered to be enrolled once the operator opens the opaque trial envelope to reveal study group assignment. After randomization, patients, treating clinicians, and study personnel are not blinded to study group assignment due to the nature of the study intervention.

STUDY INTERVENTIONS

Training:

Before beginning enrollment at each site, study investigators provide training on study procedures including instructional videos with consensus best practice recommendations for preoxygenation with noninvasive ventilation and preoxygenation with an oxygen mask. Observers receive in-person training on the collection of data during the intubation procedure using example data collection sheets. Descriptions of the training videos and website links can be found in the supplementary appendix.

Noninvasive ventilation group:

For patients assigned to the noninvasive ventilation group, operators are instructed to administer noninvasive ventilation via a tight-fitting mask covering the nose and mouth connected to either a conventional mechanical ventilator or a dedicated
noninvasive ventilator (i.e., BiPAP machine) from the initiation of preoxygenation until the initiation of laryngoscopy. The trial protocol does not dictate brand or type of ventilator, ventilator settings, or duration of preoxygenation. Operators receive the following best practice recommendations for the administration of preoxygenation using noninvasive ventilation:

1. Preoxygenate $\geq 3$ minutes (if feasible)
2. Continue noninvasive ventilation until initiation of laryngoscopy
3. Fraction of Inspired Oxygen (FiO2) of 100%
4. Expiratory pressure $\geq 5$ cm of water
5. Inspiratory pressure $\geq 10$ cm of water
6. Respiratory rate of $\geq 10$

**Oxygen mask group:**

For patients assigned to the oxygen mask group, clinicians are instructed to administer supplemental oxygen via a non-rebreather mask or bag-mask device without manual ventilation from the initiation of preoxygenation until the induction of anesthesia. The operator determines whether to use a non-rebreather mask or a bag-mask device without manual ventilation. The trial protocol does not dictate the brand or type of non-rebreather or bag-mask device or duration of preoxygenation. Between induction of anesthesia and initiation of laryngoscopy, the operator determines whether to provide oxygen with a non-rebreather mask, oxygen with a bag-mask device without manual ventilation, or oxygen with a bag-mask device with manual ventilation. Operators
receive the following best practice recommendations for the administration of preoxygenation using an oxygen mask:

1. Preoxygenate \( \geq 3 \) minutes (if feasible)
2. Maximal oxygen flow rate possible (\( \geq 15 \) liters per minute)
3. Continue oxygenation from induction to laryngoscopy

**Cointerventions:**


**Data Collection**

An observer not directly involved with the intubation procedure collects data for key periprocedural outcomes, including oxygen saturation at induction and the lowest value for oxygen saturation between induction and two minutes after successful intubation. Observers may be clinical personnel on the enrolling unit (e.g., physicians or nurses) or research personnel. Immediately after the intubation procedure, the operator
completes a paper data collection form to record the device used for preoxygenation, the duration of preoxygenation, the devices used for oxygenation and ventilation between induction and laryngoscopy, and complications of intubation. Study personnel at each site review the medical record to collect data on baseline characteristics, pre- and post-laryngoscopy management, and clinical outcomes. A complete list of baseline, peri-procedural, and in-hospital variables are provided in Supplemental Table 1.

Data on pneumothorax and new pulmonary infiltrates are collected by study staff from clinical radiology reports using a structured case report form. The clinical radiologist who interprets the chest imaging is unaware of study group assignment. A lung infiltrate is considered to be present if the clinical radiologist identifies on the chest imaging the presence of air bronchograms, centrilobular nodules, consolidation, ground-glass opacity, infiltrate, opacity, parenchymal opacification, pneumonia, pneumonitis pulmonary edema, or a tree-in-bud pattern. A pneumothorax or lung infiltrate present on chest imaging in the 24 hours after intubation will be assumed to be new if it was not present on chest imaging in the 24 hours prior to intubation. If no chest imaging is available in the 24 hours prior to intubation, any pneumothorax or lung infiltrate on chest imaging will be assumed to be new.

**Primary Outcome**
The primary outcome is the incidence of hypoxemia, defined as a peripheral oxygen saturation <85% during the interval between induction and 2 minutes after intubation.

We selected hypoxemia (as a binary variable) rather than lowest oxygen saturation (a continuous variable) as the primary outcome for the trial for several reasons. First, experiencing hypoxemia in the range associated with an increased risk of adverse clinical outcomes (e.g., cardiac arrest) may be more clinically relevant than changes in oxygen saturation within the normal range. For example a change in oxygen saturation of 5 percentage points from 87% to 82% may be more closely associated with adverse outcomes than a change in oxygen saturation of 10 percentage points from 100% to 90%. Second, values for oxygen saturation are “right-censored” because oxygen saturation reaches 100% with a partial pressure of oxygen in arterial blood (PaO₂) of approximately 100 mmHg but patients may have a higher PaO₂ following preoxygenation. The approach of analyzing hypoxemia as a binary variable rather than lowest oxygen saturation has been used by many prior trials and endorsed by airway experts.¹⁵-²⁰

We selected an oxygen saturation of <85% as the threshold for the primary outcome based on several physiologic and procedural factors. First, an oxygen saturation of 85% corresponds with the inflection point on the oxyhemoglobin dissociation curve, at which further decrements in arterial oxygen concentrations result in rapid and critical desaturation.⁹ Second, an oxygen saturation <85% has been associated with an increased risk of cardiac arrest during tracheal intubation²¹ and may be associated with increased mortality.⁵
Secondary Outcome:

The sole secondary outcome is the lowest oxygen saturation during the interval between induction and 2 minutes after tracheal intubation.

Additional Outcomes:

Table 3 reports the safety outcomes, exploratory outcomes, and clinical outcomes.

Sample Size Estimation

The minimum clinically important difference in the incidence of hypoxemia that would be required to justify routine preoxygenation with noninvasive ventilation rather than preoxygenation with an oxygen mask during the emergency tracheal intubation of critically ill adults is uncertain. The current trial is designed to detect a 6% absolute difference between groups in the incidence of hypoxemia, a difference that is similar to or smaller than the difference considered to be clinically meaningful in the design of prior trials of oxygenation strategies during tracheal intubation. Assuming an incidence of hypoxemia of 17% in the oxygen mask group based on data from two recently completed trials by this network in similar ED and ICU settings, detecting a 6% absolute decrease in the incidence of hypoxemia with 85% power at a two-sided alpha level of 0.05 would require enrollment of 1,264 patients (632 per group). Anticipating missing data for up to 3% of patients, we will plan to enroll a maximum of 1,300 total
patients (650 per group). This sample size calculation was performed in PS version 3.1.2 (Nashville, Tennessee).

**Data and Safety Monitoring Board and Interim Analysis**

A data and safety monitoring board (DSMB) consisting of members with expertise in bioethics, emergency medicine, pulmonary and critical care medicine, anesthesiology, biostatistics, and clinical trial methodology has overseen the design of the trial and is monitoring its conduct. The DSMB will review a single interim analysis, prepared by the study biostatistician at the anticipated halfway point of the trial after enrolment of 650 patients. The pre-specified stopping boundary for efficacy is a P value < 0.001 using a Chi-square test for the difference between groups in the primary outcome. This conservative Haybittle–Peto boundary will allow the final analysis to be performed using an unchanged level of significance (two-sided P value < 0.05).

The DSMB has the authority to recommend that the trial stop at any point, request additional data, request additional interim analyses, or request modifications to the study protocol.

**Statistical Analysis Principles**

Analyses will be conducted following reproducible research principles using R (R Foundation for Statistical Computing, Vienna, Austria). Categorical variables will be presented as number and percentage and compared between groups using a Chi-square test. Continuous variables will be presented as mean ± SD or median and IQR and compared between groups using a Wilcoxon Rank Sum test. We will also present
absolute between-group differences with associated 95% confidence intervals. A two-sided P-value of < 0.05 will define a statistically significant between-group difference in the primary outcome. With a single primary outcome, no adjustment for multiplicity will be made. For secondary, safety, and exploratory analyses, emphasis will be placed on the magnitude of differences between groups with 95% confidence intervals rather than statistical significance.

**Main Analysis of the Primary Outcome**

The main analysis will be an unadjusted, intention-to-treat comparison of the primary outcome of hypoxemia between patients randomized to the noninvasive ventilation group versus patients randomized to the oxygen mask group, using a chi-square test. The absolute difference in proportions, associated 95% confidence interval, and a P value for the comparison will be presented. The primary analysis will be conducted among patients for whom the primary outcome is available without imputation of missing data.

**Additional Analyses of the Primary Outcome**

*Multivariable analysis*

To account for relevant baseline covariates, we will fit a generalized linear mixed effects model using a logit link function with the primary outcome as the dependent variable, study site as a random effect, and fixed effects of study group and the following prespecified baseline covariates: age, sex, race and ethnicity, body mass index (BMI), location at enrollment (ED or ICU), highest fraction of inspired oxygen in
the hour prior to initiation of preoxygenation, Acute Physiology and Chronic Health Evaluation (APACHE) II score\textsuperscript{27}, and indication for intubation (hypoxic respiratory failure: Yes vs No). All continuous variables will be modelled assuming a non-linear relationship to the outcome using restricted cubic splines with between 3 and 5 knots.

\textit{Effect modification}

We will examine whether prespecified baseline variables modify the effect of study group assignment (noninvasive ventilation vs oxygen mask) on the primary outcome using a formal test of statistical interaction in a generalized linear mixed-effects model with the primary outcome as the dependent variable, study site as a random effect and fixed effects of study group, the prespecified proposed effect modifier and the interaction between the two. For categorical variables, we will present the OR and 95\% CIs within each prespecified subgroup. Continuous variables will not be dichotomized for analysis of effect modification but may be dichotomized for data presentation. In accordance with the Instrument for assessing the Credibility of effect Modification Analyses (ICEMAN) recommendations, we have prespecified the following baseline variables as potential effect modifiers and hypothesized the direction of effect modification for each:

1. \textbf{Patient location (ED vs ICU)}. We hypothesize that patient location will not modify the effect of study group assignment on the primary outcome.

2. \textbf{Body Mass Index (kg/m\textsuperscript{2})}. We hypothesize that Body Mass Index (BMI) will modify the effect of study group assignment on the primary outcome, with a greater decrease in the incidence of hypoxemia with preoxygenation within the
noninvasive ventilation group compared to the oxygen mask group among patients with higher BMIs, as compared to patients with lower BMIs. This hypothesis of effect modification is supported by evidence from multiple prior studies that patients with obesity are more likely to have early airway closure and atelectasis-dependent shunting that is likely to improve with positive pressure ventilation. 28,29

3. **Fraction of inspired oxygen in the hour prior to intubation**. We hypothesize that the fraction of inspired oxygen received in the hour prior to intubation will modify the effect of study group assignment on the primary outcome, with a greater decrease in the incidence of hypoxemia in the noninvasive ventilation group compared to the oxygen mask group among patients with higher fractions of inspired oxygen in the hour prior to intubation, compared to patients with lower fractions of inspired oxygen. This hypothesis of effect modification is supported by evidence from multiple prior studies that patients requiring higher fractions of inspired oxygen have more atelectasis-dependent shunting that is likely to improve with positive pressure ventilation.5,11,30

4. **APACHE II score**. We hypothesize that APACHE II score will not modify the effect of study group assignment on the primary outcome.

5. **Hypoxemic respiratory failure as the indication for intubation (Yes vs No)**. We hypothesize that hypoxemic respiratory failure as the indication for intubation will modify the effect of study group assignment on the primary outcome, with a greater decrease in the incidence of hypoxemia in the noninvasive ventilation group compared to the oxygen mask group among patients with hypoxemic
respiratory failure, compared to patients without. This hypothesis of effect modification is supported by evidence from two prior randomized trials suggesting a potential benefit for noninvasive ventilation among patients with acute hypoxemic respiratory failure.\textsuperscript{11,12}

**Analysis of the Secondary Outcome**

We will perform an unadjusted, intention-to-treat comparison of patients randomized to the noninvasive ventilation group versus the oxygen mask group with regard to the secondary outcome of lowest oxygen saturation between induction and 2 minutes after intubation using the Wilcoxon rank sum test.

**Analyses of Additional Outcomes:**

We will conduct unadjusted, intention-to-treat analyses comparing patients randomized to the noninvasive ventilation group versus the oxygen mask group with regard to all pre-specified safety, clinical, and exploratory outcomes. Continuous outcomes will be compared with the Wilcoxon rank sum test and categorical variables with the chi-square test. Between-group differences in continuous and categorical variables and the associated 95% confidence intervals will be presented.

**Handling of missing data:**

We anticipate that no patients will be lost to follow up before assessment of the primary outcome. In some cases, the oxygen saturation between induction and 2 minutes after intubation will be unmeasurable (e.g., poor plethysmography of pulse
oximetry, shock, cardiac arrest, peripheral arterial disease, or other reasons) or unavailable. We anticipate that data will be missing in less than 3% of cases based on the rates of missing data in prior trials in similar settings. Missing data will not be imputed for the primary outcome or for any of the secondary or exploratory outcomes. In adjusted analyses, missing data for baseline covariates will be imputed using multiple imputations.

**Trial status:**

PREOXI is a pragmatic, multi-center, non-blinded randomized clinical trial comparing preoxygenation with noninvasive ventilation to preoxygenation with an oxygen mask during the tracheal intubation of critically ill adults. Enrollment began on 10 March 2022 and is expected to conclude in 2023.

**ETHICS AND DISSEMINATION**

**Waiver of Informed Consent:**

Critically ill patients undergoing tracheal intubation in the ED or ICU are at significant risk for morbidity and mortality from their underlying illness. Most patients undergoing tracheal intubation in routine clinical care receive preoxygenation with either noninvasive ventilation or an oxygen mask. Any benefits or risks of these two approaches are experienced by patients undergoing tracheal intubation in clinical care, outside the context of research. As a requirement for enrollment in PREOXI, the patient’s treating clinician must determine that either preoxygenation with noninvasive
ventilation or preoxygenation with an oxygen mask would be a safe and reasonable approach for the patient (otherwise the patient is excluded). Therefore, making the decision between the two approaches randomly in the context of a pragmatic trial, rather than by a clinician who thinks either approach is safe and reasonable for the patient, is expected to pose no more than minimal additional risk.

Obtaining informed consent from potential study participants or their legally authorized representatives would be impracticable. The majority of critically ill patients undergoing emergency tracheal intubation lack decisional capacity due to their critical illness and surrogate decision makers are frequently unavailable. Further, emergency tracheal intubation is a time-sensitive procedure with only minutes between the decision to intubate and the completion of the procedure. Meaningful informed consent could not be executed in this brief window. Attempting to obtain informed consent could lead to potentially deleterious delays in intubation which would increase the risk of hypoxemia, hypotension, and cardiac arrest.

Because the study involves minimal incremental risk, the study would not adversely affect the welfare or privacy rights of the participant, and obtaining informed consent would be impracticable, a waiver of informed consent was requested from and approved by the single institutional review board at Vanderbilt University Medical Center (reference number VUMC IRB# 211271). Conduct of this trial with waiver of informed consent is consistent with previous randomized trials comparing alternative approaches to tracheal intubation in widespread clinical use. This approach was secondarily approved by the US Department of Defense Health Agency Human Research Protection Office). IRBs at participating sites reviewed the protocol,
addressed any local contextual factors with the site principal investigator, and ceded responsibility for ethics approval and study oversight to the single IRB.

**Information for Patients and Families**

Information regarding the study is made available to patients and families following intubation using a patient and family information sheet. The patient and family information sheet contains information on the purpose of the PREOXI trial, study procedures, risks and discomforts, benefits, use of protected health information, confidentiality, and investigator contact information. The Defense Health Agency Human Research Protection Office determined that this procedure meets the requirement of 32 CFR 219 and DODI 3216.02_AFI40-402. At centers with a significant population of non-English speaking patients, the patient and family information sheet has been translated into Spanish and Somali languages.

**Protocol Changes**

In accordance with SPIRIT guidelines, changes to the study protocol will be documented on clinicaltrials.gov (see online supplementary file) and submitted to the sIRB for approval.

**Data Handling**

Privacy protocols and data handling are reported in the online supplement.

**Dissemination Plan**
We will submit the trial results to a peer-reviewed journal for publication. Trial results will also be presented at scientific conferences and disseminated online and via social media in forms suitable for public understanding.

Conclusion

The PREOXI trial will provide important data on the effectiveness of common preoxygenation strategies for the prevention of hypoxemia during emergency tracheal intubation with a goal of improving outcomes for critically ill adults. To aid in the transparency and interpretation of trial results, this protocol and statistical analysis plan for the PREOXI trial has been finalized prior to the conclusion of patient enrollment.
REFERENCES


<table>
<thead>
<tr>
<th>Timepoint</th>
<th>Eligibility Screen</th>
<th>Randomization and Allocation</th>
<th>Peri-Procedural</th>
<th>Final Outcome Assessment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Enrollment:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eligibility screen</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Allocation</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Interventions:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Preoxygenation with NIPPV</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Preoxygenation with facemask oxygen</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Screening for contraindications</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Assessments:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline variables</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peri-procedural variables</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Adverse events</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Clinical outcomes</td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
</tr>
</tbody>
</table>

Table 1: Schedule of Enrollment, Interventions, and Assessments in PREOXI

- Decision to perform tracheal intubation
- Before tracheal intubation
- Induction
- Tracheal intubation
- 0-2 min after tracheal intubation
- 0-24 hours after tracheal intubation
- Discharge or 28 days after enrollment
### Table 2: Inclusion/Exclusion Criteria

<table>
<thead>
<tr>
<th>Inclusion Criteria</th>
<th>Exclusion Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient is located in a participating unit.</td>
<td>Patient is known to be less than 18 years old.</td>
</tr>
<tr>
<td>Planned procedure is tracheal intubation using a laryngoscope and sedation.</td>
<td>Patient is known to be pregnant.</td>
</tr>
<tr>
<td>Planned operator is a clinician expected to routinely perform tracheal intubation in the participating unit.</td>
<td>Patient is known to be a prisoner.</td>
</tr>
<tr>
<td>Immediate need for tracheal intubation precludes safe performance of study procedures.</td>
<td>Patient is apneic, hypopneic, or has another condition requiring positive pressure ventilation between enrollment and induction.</td>
</tr>
<tr>
<td>Operator has determined that preoxygenation with noninvasive ventilation or preoxygenation with an oxygen mask is required or contraindicated for optimal care of the patient.</td>
<td></td>
</tr>
</tbody>
</table>

### Table 3: Study outcomes

<table>
<thead>
<tr>
<th>Primary Outcome</th>
<th>Incidence of hypoxemia, defined as a peripheral oxygen saturation &lt;85% during the interval between induction and 2 minutes after tracheal intubation.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Secondary Outcome</td>
<td>Lowest oxygen saturation during the interval between induction and 2 minutes after tracheal intubation.</td>
</tr>
<tr>
<td>Safety Outcomes</td>
<td>Incidence of operator-reported aspiration.</td>
</tr>
<tr>
<td></td>
<td>Fraction of inspired oxygen at 24 hours after induction.</td>
</tr>
<tr>
<td></td>
<td>Oxygen saturation at 24 hours after induction.</td>
</tr>
<tr>
<td></td>
<td>Incidence of pneumothorax, defined as radiology report of new pneumothorax on chest imaging in the 24 hours after induction. If no chest imaging available pre-induction, any pneumothorax in the 24 hours after induction will be assumed to be new.</td>
</tr>
<tr>
<td></td>
<td>New infiltrate, defined as radiology report of new infiltrate on chest imaging in the 24 hours after intubation. If no chest imaging available pre-induction, any infiltrate in the 24 hours after induction will be assumed to be new.</td>
</tr>
<tr>
<td>Exploratory Outcomes</td>
<td>Incidence of severe hypoxemia, defined as the lowest oxygen saturation of &lt;80% between induction and 2 minutes after tracheal intubation.</td>
</tr>
<tr>
<td><strong>Incidence of very severe hypoxemia</strong>, defined as the lowest oxygen saturation of &lt;70% between induction and 2 minutes after tracheal intubation.</td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td><strong>Oxygen saturation at induction.</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Systolic blood pressure at induction.</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Duration from induction to successful intubation (duration of the intubation procedure).</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Cormack-Lehane grade of glottic view on first attempt.</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Number of laryngoscopy attempts.</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Number of attempts at passing a bougie.</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Number of attempts at passing an endotracheal tube.</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Incidence of cardiovascular collapse</strong>, defined as a composite of one or more of the following between induction and 2 minutes after intubation: Systolic blood pressure &lt;65 mmHg, new or increased vasopressor, cardiac arrest not resulting in death within 1 hour of induction, cardiac arrest resulting in death within 1 hour of induction.</td>
<td></td>
</tr>
<tr>
<td><strong>28 day in-hospital mortality.</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Ventilator-free days to 28 days.</strong></td>
<td></td>
</tr>
<tr>
<td><strong>ICU-free days to 28 days.</strong></td>
<td></td>
</tr>
</tbody>
</table>